AN2728 Topical Ointment, 2%

DRUG3 trials

Sponsors

Pfizer

Conditions

Dermatitis, Atopic

Phase 1

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

CompletedNCT01652885

PfizerDermatitis, Atopic

Start: 2012-07-31End: 2012-11-30Updated: 2017-04-24

Phase 3

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

CompletedNCT02118766

PfizerDermatitis, Atopic

Start: 2014-03-31End: 2015-04-30Updated: 2017-03-06

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

CompletedNCT02118792

PfizerDermatitis, Atopic

Start: 2014-03-31End: 2015-04-30Updated: 2017-03-06

Related Papers

Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis

Dermatitis2024-01-115 citations

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study

American Journal of Clinical Dermatology2023-05-1533 citations

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.

2023-02-223 citations

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.

2022-03-1613 citations

Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities

Allergy and Asthma Proceedings2021-09-0111 citations

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis

Dermatology and Therapy2021-08-1111 citations

Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.

2021-03-131 citations

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

Pediatric Dermatology2020-09-2711 citations

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).

2020-04-0155 citations

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area

Acta Dermato Venereologica2020-01-0113 citations

Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.

2019-07-0712 citations

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis

Acta Dermato Venereologica2019-01-0111 citations

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families.

2018-10-2218 citations

Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS)

Itch2018-06-0114 citations

Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials

Itch2018-06-019 citations

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

2016-07-11356 citations